DVAX
Dynavax TechnologiesยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
DVAX Profile
Dynavax Technologies Corporation
A biotech company that develops and commercializes vaccines and immune-oncology therapies
2100 Powell Street, Suite 720, Emeryville, CA 94608
--
Dynavax Technologies Corporation was incorporated on August 29, 1996 under the name of California Double Helix Structure Corporation and changed its name to Dynavax Technologies Corporation in September 1999. The company was restructured in Delaware in 2000. The Company is a fully integrated biopharmaceutical company focused on harnessing the power of the body's innate and adaptive immune responses through Toll-like receptor (" TLR ") stimulation. Their first commercial product, HEPLISAV-B (hepatitis B vaccine (reconstituted), adjuvant), was approved by the U.S. Food and Drug Administration (" FDA ") in November 2017 for the prevention of infection caused by all known hepatitis B subtypes of the virus in adults over the age of 18 years. They started shipping HEPLISAV-B commercially in January 2018. Their development work has focused on stimulating the innate immune response to treat cancer in combination with other immunomodulators. Their main research immuno-oncology product is SD-101, which is currently undergoing Phase 2 clinical study evaluation, and DV281 is undergoing Phase 1 safety study.
